AHK-Cu

Typical use cases

Dosing guidelines

Titration

No formal titration is described in the literature; people in community settings often report starting at a low concentration (e.g., ~0.05–0.5%) to assess skin/scalp tolerance before using higher-percentage serums.

Reconstitution

N/A for finished topical serums. For raw powder, sources describe dissolving in distilled/deionized water, keeping pH ~5.5–7.0, adding during the cool-down phase of a formulation (<40°C), and storing in a dark glass container.

Injection sites

Topical — applied to the scalp or skin; not an injectable compound.

Storage & handling

Store powder cool, dry, and protected from light. Reconstituted/finished serums are commonly kept refrigerated (2–8°C) in a dark glass container away from heat and light, with use typically within ~30 days.

Side effects

• Scalp or skin irritation / redness Mild · Uncommon
• Contact dermatitis or allergic skin reaction Mild · Rare
• Itching at application site Mild · Uncommon
• Transient increased shedding early in use Mild · Uncommon
• Theoretical copper accumulation with excessive/prolonged high-dose topical use Moderate · Rare

Research summary

The evidence base for AHK-Cu is small and almost entirely preclinical, with no published randomized human clinical trials of the compound on its own. The most-cited primary study (Pyo et al., Archives of Pharmacal Research, 2007) reported that AHK-Cu at picomolar-to-nanomolar concentrations (10⁻¹² to 10⁻⁹ M) stimulated elongation of human hair follicles in ex vivo organ culture and increased proliferation of cultured dermal papilla cells (DPCs). In that work AHK-Cu was associated with a higher anti-apoptotic Bcl-2/Bax ratio and lower cleaved caspase-3 and PARP, suggesting reduced DPC apoptosis, though the apoptosis reduction did not reach statistical significance. Mechanistically, the tripeptide is generally described as a copper-delivery vehicle that supplies Cu²⁺ as a cofactor for copper-dependent enzymes such as lysyl oxidase (collagen/elastin cross-linking) and superoxide dismutase, while reportedly modulating growth-factor signaling (e.g., increasing VEGF and lowering TGF-β1 in dermal fibroblasts). It differs structurally from the better-known GHK-Cu only by an alanine-for-glycine substitution at the N-terminus. Much of the mechanistic and clinical context is extrapolated from the closely related GHK-Cu literature rather than from direct AHK-Cu studies. Key limitations are the absence of standalone human efficacy trials, reliance on cell-culture and organ-culture models, and the fact that most real-world use is in multi-ingredient cosmetic serums, making isolated benefit hard to attribute.

Key references

• https://pubmed.ncbi.nlm.nih.gov/17703734/
• https://doi.org/10.1007/BF02978833
• https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
• https://peptideinsight.com/en/peptides/copper-tripeptide-1
• https://peptide-db.com/peptides/ahk-cu

Related compounds